跳至主要内容
临床试验/NCT03043287
NCT03043287已完成不适用

Voiding Efficiency, a Predictor of CIC

Allergan3 个研究点 分布在 1 个国家目标入组 420 人开始时间: 2017年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Allergan
入组人数
420
试验地点
3
主要终点
Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX®

研究概览

简要总结

This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with documented idiopathic OAB diagnosis
  • Patient was treated with 100-200U of BOTOX® for OAB
  • Urodynamics assessment within prior to first BOTOX® injection.

排除标准

  • Patient had received botulinum toxin formulations other than BOTOX® in the bladder
  • Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

结局指标

主要结局

Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX®

时间窗: 12 Weeks

Pre-BOTOX® Injection VE Cutoff-Ratios that Predict the Risk of CIC following Treatment with 100-200U of BOTOX®

时间窗: Pre-BOTOX® Injection (Baseline)

VE was calculated as the ratio of voided volume to the total bladder capacity.

次要结局

未报告次要终点

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

Voiding Efficiency, a Predictor of Clean... | 临床试验